Janney Montgomery Scott LLC Biomarin Pharmaceutical Inc Transaction History

Janney Montgomery Scott LLC

  • $35.8 Billion
  • Q3 2024

A detailed history of Janney Montgomery Scott LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Janney Montgomery Scott LLC holds 11,700 shares of BMRN stock, worth $779,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,700
Previous 5,789 102.11%
Holding current value
$779,922
Previous $477,000 72.33%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024
BUY
$69.02 - $93.84 $407,977 - $554,688
5,911 Added 102.11%
11,700 $822,000
Q2 2024

Jul 25, 2024
SELL
$74.43 - $92.22 $195,974 - $242,815
-2,633 Reduced 31.26%
5,789 $477,000
Q1 2024

May 01, 2024
SELL
$83.81 - $99.0 $22,293 - $26,334
-266 Reduced 3.06%
8,422 $736,000
Q4 2023

Feb 07, 2024
SELL
$76.22 - $98.51 $21,341 - $27,582
-280 Reduced 3.12%
8,688 $837,000
Q3 2023

Nov 08, 2023
SELL
$85.07 - $94.48 $4,848 - $5,385
-57 Reduced 0.63%
8,968 $793,000
Q2 2023

Jul 26, 2023
SELL
$86.68 - $100.3 $11,528 - $13,339
-133 Reduced 1.45%
9,025 $782,000
Q1 2023

Apr 28, 2023
SELL
$87.74 - $117.27 $127,310 - $170,158
-1,451 Reduced 13.68%
9,158 $891,000
Q4 2022

Feb 01, 2023
SELL
$80.93 - $108.63 $30,996 - $41,605
-383 Reduced 3.48%
10,609 $1.1 Million
Q3 2022

Oct 25, 2022
BUY
$82.16 - $96.94 $131,702 - $155,394
1,603 Added 17.07%
10,992 $932,000
Q2 2022

Aug 03, 2022
SELL
$71.48 - $86.85 $239,743 - $291,294
-3,354 Reduced 26.32%
9,389 $780,000
Q1 2022

May 04, 2022
SELL
$74.28 - $92.69 $1.65 Million - $2.06 Million
-22,197 Reduced 63.53%
12,743 $982,000
Q4 2021

Jan 27, 2022
SELL
$71.72 - $91.47 $61,177 - $78,023
-853 Reduced 2.38%
34,940 $3.09 Million
Q3 2021

Oct 29, 2021
BUY
$74.77 - $85.47 $122,697 - $140,256
1,641 Added 4.8%
35,793 $2.77 Million
Q2 2021

Jul 26, 2021
BUY
$75.51 - $84.79 $686,989 - $771,419
9,098 Added 36.31%
34,152 $2.85 Million
Q1 2021

Apr 27, 2021
BUY
$74.73 - $90.69 $87,807 - $106,560
1,175 Added 4.92%
25,054 $1.89 Million
Q4 2020

Jan 25, 2021
SELL
$72.61 - $90.2 $485,180 - $602,716
-6,682 Reduced 21.86%
23,879 $2.09 Million
Q3 2020

Nov 06, 2020
SELL
$71.87 - $131.03 $2.33 Million - $4.25 Million
-32,427 Reduced 51.48%
30,561 $2.33 Million
Q2 2020

Jul 23, 2020
BUY
$79.55 - $124.22 $3.48 Million - $5.43 Million
43,750 Added 227.41%
62,988 $7.77 Million
Q1 2020

Apr 30, 2020
BUY
$71.37 - $96.85 $124,968 - $169,584
1,751 Added 10.01%
19,238 $1.63 Million
Q4 2019

Jan 21, 2020
SELL
$64.27 - $86.37 $88,114 - $118,413
-1,371 Reduced 7.27%
17,487 $1.48 Million
Q3 2019

Oct 29, 2019
BUY
$67.4 - $85.11 $475,911 - $600,961
7,061 Added 59.85%
18,858 $1.27 Million
Q2 2019

Jul 29, 2019
BUY
$80.35 - $93.9 $390,259 - $456,072
4,857 Added 69.99%
11,797 $1.01 Million
Q1 2019

Apr 30, 2019
BUY
$84.2 - $98.62 $22,565 - $26,430
268 Added 4.02%
6,940 $616,000
Q4 2018

Feb 01, 2019
SELL
$80.14 - $106.07 $146,095 - $193,365
-1,823 Reduced 21.46%
6,672 $568,000
Q3 2018

Nov 05, 2018
SELL
$93.92 - $105.72 $75,136 - $84,576
-800 Reduced 8.61%
8,495 $824,000
Q2 2018

Jul 24, 2018
SELL
$76.01 - $99.03 $110,214 - $143,593
-1,450 Reduced 13.49%
9,295 $876,000
Q1 2018

Apr 19, 2018
BUY
$77.67 - $92.63 $98,174 - $117,084
1,264 Added 13.33%
10,745 $871,000
Q4 2017

Feb 14, 2018
SELL
$80.76 - $95.13 $62,508 - $73,630
-774 Reduced 7.55%
9,481 $845,000
Q3 2017

Nov 15, 2017
BUY
$80.6 - $94.95 $826,552 - $973,712
10,255
10,255 $954,000

Others Institutions Holding BMRN

# of Institutions
622
Shares Held
180M
Call Options Held
1.42M
Put Options Held
1.26M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Janney Montgomery Scott LLC Portfolio

Follow Janney Montgomery Scott LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email